5,10,15,20-Tetrakis(4-sulfonatophenyl)porphyrin Zinc and Chloro-aluminum Phthalocyanine Disulfonate in Photodynamic Therapy of Colorectal Adenocarcinoma In Vitro.

IF 1.6 4区医学 Q4 ONCOLOGY Anticancer research Pub Date : 2024-10-01 DOI:10.21873/anticanres.17263

Jakub Hosik, Barbora Hosikova, Hana Kolarova, Robert Bajgar

{"title":"5,10,15,20-Tetrakis(4-sulfonatophenyl)porphyrin Zinc and Chloro-aluminum Phthalocyanine Disulfonate in Photodynamic Therapy of Colorectal Adenocarcinoma In Vitro.","authors":"Jakub Hosik, Barbora Hosikova, Hana Kolarova, Robert Bajgar","doi":"10.21873/anticanres.17263","DOIUrl":null,"url":null,"abstract":"Background/aim: Colorectal cancer (CRC) is one of the most widespread malignancies. One of the alternative therapeutic methods appears to be photodynamic therapy (PDT).Materials and methods: This study investigated the efficiency of 5,10,15,20-tetrakis(4-sulfonatophenyl)porphyrin zinc (ZnTPPS4) and chloro-aluminum phthalocyanine disulfonate (ClAlPcS2) with two commercial photosensitive compounds 5,10,15,20-tetrakis(1-methylpyridinium-4-yl)porphyrin (TMPyP) and tetramethylthionine chloride (methylene blue, MB) in PDT for CRC in vitro. In addition to the study of the photodynamic effect on the viability of the colorectal carcinoma cell line HT29, cellular uptake, ROS production, and DNA damage were investigated.Results: All photosensitizers showed good accumulation within HT29 cells, high efficiency in killing the cells, and a concentration-dependent increase in the production of ROS.Conclusion: PDT using ZnTPPS4 and ClAlPcS2 may be effective in the treatment of CRC, achieving a similar photocytotoxic effect at much lower concentrations compared to MB.","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"44 10","pages":"4339-4346"},"PeriodicalIF":1.6000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Anticancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21873/anticanres.17263","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background/aim: Colorectal cancer (CRC) is one of the most widespread malignancies. One of the alternative therapeutic methods appears to be photodynamic therapy (PDT).

Materials and methods: This study investigated the efficiency of 5,10,15,20-tetrakis(4-sulfonatophenyl)porphyrin zinc (ZnTPPS₄) and chloro-aluminum phthalocyanine disulfonate (ClAlPcS₂) with two commercial photosensitive compounds 5,10,15,20-tetrakis(1-methylpyridinium-4-yl)porphyrin (TMPyP) and tetramethylthionine chloride (methylene blue, MB) in PDT for CRC in vitro. In addition to the study of the photodynamic effect on the viability of the colorectal carcinoma cell line HT29, cellular uptake, ROS production, and DNA damage were investigated.

Results: All photosensitizers showed good accumulation within HT29 cells, high efficiency in killing the cells, and a concentration-dependent increase in the production of ROS.

Conclusion: PDT using ZnTPPS₄ and ClAlPcS₂ may be effective in the treatment of CRC, achieving a similar photocytotoxic effect at much lower concentrations compared to MB.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

5,10,15,20-四(4-磺酸苯基)卟啉锌和酞菁二磺酸氯铝在体外大肠腺癌光动力疗法中的应用

背景/目的：结直肠癌（CRC）是最常见的恶性肿瘤之一。光动力疗法（PDT）似乎是替代治疗方法之一：本研究调查了5,10,15,20-四（4-磺酸苯基）卟啉锌（ZnTPPS4）和氯铝酞菁二磺酸盐（ClAlPcS2）与两种商用光敏化合物5,10,15,20-四（1-甲基吡啶鎓-4-基）卟啉（TMPyP）和四甲基亚硫酰氯（亚甲蓝，MB）在体外光动力疗法治疗 CRC 中的效率。除了研究光动力效应对结直肠癌细胞株 HT29 的存活率的影响外，还研究了细胞吸收、ROS 生成和 DNA 损伤：结果：所有光敏剂在 HT29 细胞内都有很好的积累，杀灭细胞的效率很高，ROS 的产生随浓度增加而增加：结论：使用 ZnTPPS4 和 ClAlPcS2 的光导疗法可有效治疗 CRC，与 MB 相比，它们能以更低的浓度达到类似的光细胞毒性效果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Anticancer research 医学-肿瘤学

CiteScore

3.70

自引率

10.00%

发文量

566

审稿时长

2 months

期刊介绍： ANTICANCER RESEARCH is an independent international peer-reviewed journal devoted to the rapid publication of high quality original articles and reviews on all aspects of experimental and clinical oncology. Prompt evaluation of all submitted articles in confidence and rapid publication within 1-2 months of acceptance are guaranteed. ANTICANCER RESEARCH was established in 1981 and is published monthly (bimonthly until the end of 2008). Each annual volume contains twelve issues and index. Each issue may be divided into three parts (A: Reviews, B: Experimental studies, and C: Clinical and Epidemiological studies). Special issues, presenting the proceedings of meetings or groups of papers on topics of significant progress, will also be included in each volume. There is no limitation to the number of pages per issue.